Cargando…

P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales:	Weisel, Katja, D’souza, Anita, Hurd, David, Voorhees, Peter, Teipel, Raphael, Chung, Alfred, Rodriguez, Cesar, Tuchman, Sacha, Korde, Neha, Safah, Hana, Bueno, Orlando, Feng, Zhongling, Rosenberg, Tanya, Kumar Pothacamury, Rajvineeth, Ross, Jeremy, Lee, Shane, Jin, Ziyi, Talati, Chetasi, Kumar, Shaji, Vij, Ravi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431066/ http://dx.doi.org/10.1097/01.HS9.0000970352.00363.07

Ejemplares similares

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
por: D'Souza, Anita, et al.
Publicado: (2022)

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION
por: Valdes, Cesar Rodriguez, et al.
Publicado: (2023)

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma
por: Foureau, David M., et al.
Publicado: (2020)

CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy
por: de Poel, Eyleen, et al.
Publicado: (2021)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

P862: SERUM MASS SPECTROMETRY TO ANALYZE DISEASE RESPONSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING ARI0002H, AN ACADEMIC BCMA-DIRECTED CAR T-CELL THERAPY
por: Ortiz De Landazuri, I., et al.
Publicado: (2022)

862. Spatial Distribution of HIV Transmission in Ethiopia and Characteristics of HIV Clusters
por: Ying, Roger, et al.
Publicado: (2018)

A novel gene ZNF862 causes hereditary gingival fibromatosis
por: Wu, Juan, et al.
Publicado: (2022)

Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives
por: Talati, Chetasi, et al.
Publicado: (2018)

Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas
por: Martens, Anne W.J., et al.
Publicado: (2022)

Incidence of chest wall deformity in 15,862 students in the province of Sivas, Türkiye
por: Katrancioglu, Ozgur, et al.
Publicado: (2023)

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
por: Deplanque, G, et al.
Publicado: (2004)

Gaia Data Release 3 - Exploring and mapping the diffuse interstellar band at 862 nm
por: Schultheis, M., et al.
Publicado: (2023)

POS-862 PREVALENCE AND FACTORS ASSOCIATED WITH RHABDOMYOLYSIS IN COVID-19 PATIENTS: AN OBSERVATIONAL STUDY
por: Mboliassa, M.F., et al.
Publicado: (2022)

In vivo kinetics of Wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae
por: Hübner, Marc P., et al.
Publicado: (2019)

Transcriptome Analysis of Duck and Chicken Brains Infected with Aquatic Bird Bornavirus-1 (ABBV-1)
por: Pham, Phuc H., et al.
Publicado: (2022)

Proton-proton scattering at 383 Mev
por: Holt, J R, et al.
Publicado: (1956)

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Dalovisio, A., et al.
Publicado: (2022)

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
por: Baumgartner, Christina K., et al.
Publicado: (2023)

862 Alcohol-Impregnated Disinfectant Caps Reduce The Rate Of Central-Line Associated Bloodstream Infections And Nosocomial Bacteremia
por: Shelly, Mark, et al.
Publicado: (2014)

862. Impact of Caregiver Health on Pediatric Healthcare-Associated Viral Respiratory Infections (HAVRIs): A Retrospective Study
por: Paquette, Maude, et al.
Publicado: (2020)

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
por: Luke, Jason J, et al.
Publicado: (2021)

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)
por: Powderly, John, et al.
Publicado: (2020)

Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients
por: Yuda, Junichiro, et al.
Publicado: (2023)

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
por: Cho, Shih-Feng, et al.
Publicado: (2018)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

Was wird mit GOÄ-Ziffer A383 anders?
por: Zimmermann, Gerd W.
Publicado: (2022)

Differential Diagnosis: Presented through an Analysis of 383 Cases
Publicado: (1911)

383 SLE After SARS-COV-2 Infection
Publicado: (2022)

BCMA-targeted immunotherapy for multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity
por: von Geldern, Thomas W., et al.
Publicado: (2019)

Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators
por: de Wilde, Gert, et al.
Publicado: (2019)

ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19
por: Fakhar, Zeynab, et al.
Publicado: (2021)

PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY
por: Mascarenhas, John, et al.
Publicado: (2023)

Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report
por: Li, Dan, et al.
Publicado: (2022)

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
por: Visram, A., et al.
Publicado: (2021)

Positive pion production in p-p collisions at 383 Mev
por: Alston, M H, et al.
Publicado: (1956)

Refining Kidney Survival in 383 Genetically Characterized Patients With Nephronophthisis
por: König, Jens Christian, et al.
Publicado: (2022)

Anti-BCMA novel therapies for multiple myeloma
por: Sammartano, Vincenzo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0rprmplrqpd8ifg0ejmjfuampu